Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

somapacitan

- PMLiVE

Xtandi slowdown weighs on Pfizer, but CEO won’t move on M&A

Investors call on the pharma giant to consider a large merger or acquisition deal

translational pharmacology medicine dose

Audit exposes gaps in pharma’s promises on trial transparency

Study group estimates nearly half of all clinical trials go unpublished

A healthcare landscape going through seismic change

Pfizer’s quest to generate health innovation as an ageing demographic threatens society’s ability to treat people

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Novo launches personalised diabetes management mobile app

Partners with Glooko on app that syncs blood glucose and activity data

- PMLiVE

FDA panel backs CV claims for Novo Nordisk’s Victoza

LEADER trial shows the diabetes treatment reduces risk of cardiovascular death by 13%

Can Cinderella save us?

Basilea bags $72m upfront from Pfizer for antifungal license

Pfizer will also pay $427m in future milestone payments for Cresemba

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

- PMLiVE

Taking a lean and careful approach

Kunwar Shailubhai on why biotech is a roller coaster and how Tiziana Life Sciences is pursuing its mission to tackle unmet needs

- PMLiVE

Pfizer hits accelerator on Xtandi trial in early prostate cancer

US pharma giant expects PROSPER trial results later this year

- PMLiVE

Novo says real-world data backs its insulin switching

EU-TREAT study shows Tresiba improved blood glucose control

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links